L&K Biomed Succeeds in First U.S. Clinical Application of "BluEX-C," Accelerates Global Market Expansion
L&K Biomed, a spinal implant specialist, has accelerated its entry into the global cervical implant market by successfully completing the first clinical application of its height-expandable cervical cage, "BluEX-C," in the United States. The company received approval from the U.S. Food and Drug Administration (FDA), and within about a month, the device was used in an actual surgical procedure, demonstrating its potential for commercialization.
L&K Biomed (CEO Kang Gukjin) announced on July 1 that it had successfully completed the first clinical surgery using "BluEX-C" at Adventist Health White Memorial Hospital in California, USA.
This procedure marks the first time the height-expandable (Expandable) cervical cage "BluEX-C," which received FDA approval in May, has been applied in a U.S. medical setting. The swift transition from approval to hospital registration and clinical use is seen as the company's first achievement in demonstrating the speed of its U.S. market entry and commercial competitiveness.
This surgical case is expected to be featured in U.S. spine-focused media outlets such as Becker's Spine and Spine Market Group, which will help highlight the product's technological capabilities and attract interest from local medical professionals.
Dr. Mohsin Fidai, a U.S. spine specialist with extensive experience in cervical and lumbar disease treatment and minimally invasive surgery, performed the first procedure. Through anterior cervical discectomy and fusion (ACDF), he removed the damaged disc at the C5-C6 region of the patient and successfully inserted the smallest size, a 4mm "BluEX-C" from L&K Biomed, adjusting the disc space and cervical alignment.
ACDF is the most widely performed standard surgery for cervical disease and is routinely used by most spine surgeons. As a result, "BluEX-C" can be applied without modifying existing surgical techniques, offering greater accessibility for medical professionals and potentially enabling faster market adoption compared to lumbar products.
In contrast, lumbar surgeries are divided into various approaches, including posterior (TLIF, PLIF), lateral (LLIF), anterior to psoas (ATP), and anterior (ALIF), with product application segmented by each surgeon's preferred technique. "BluEX-C" stands out because it can be used in the existing ACDF surgical environment without such approach limitations.
"BluEX-C" is securing competitiveness in the global market for height-expandable cervical cages, where there are few commercialized products worldwide. Currently, only a handful of such products, including L&K Biomed's, are available globally. The company emphasizes its broad size lineup as a key advantage, enabling it to accommodate a wide range of surgical cases compared to competing products.
A company representative stated, "Drawing on the experience gained from the previous XTP project, we have significantly improved the completeness of 'BluEX-C.' Since ACDF surgeries can utilize existing instruments, there is minimal burden to develop dedicated instruments, and if additional solutions are needed, we can quickly develop them using our in-house technology."
The representative added, "The previous XTP project is also being further developed to enhance completeness by addressing risks related to dedicated instruments and retractors."
Notably, "BluEX-C" was registered with hospitals at a premium price approximately four to five times higher than that of standard cervical cages commonly used in large U.S. hospitals. This is not simply a matter of higher pricing, but rather recognition of the product's differentiated technology and value in the market.
Having succeeded in being selected as a premium product by hospitals, the company expects that as the number of medical institutions adopting the device and the volume of supply increase, both revenue growth and profitability will be positively impacted.
ACDF is the most commonly performed cervical fusion surgery worldwide and is a core segment of the global cervical implant market. In particular, the U.S. market is the world's largest for medical devices, estimated to be worth about USD 1.13 billion (approximately KRW 1.5 trillion) in 2025. The market is expected to grow at a compound annual rate of 3.9%, reaching approximately USD 1.6 billion (about KRW 2.2 trillion) by 2034-2035.
A spokesperson for L&K Biomed commented, "This achievement is the result of about four years of effort since we first attempted to obtain FDA approval for a height-expandable cervical cage in 2022. This first clinical application marks an important starting point for confirming the commercial potential of 'BluEX-C' in the U.S. market."
The spokesperson added, "Since FDA approval, hospital registration, first clinical use, and additional surgical schedules have been progressing sequentially in a short period. We plan to rapidly secure initial references, expand the number of hospitals and supply volume, and maintain a premium pricing policy to increase the proportion of high value-added sales."
L&K Biomed is advancing its "New Cervical Project" to expand its presence in the global cervical market. By adding "BluEX-C" to its existing cervical product lineup, the company aims to shift its business structure from standard cervical cages to premium height-expandable products, establishing the cervical segment as a new growth axis.
Additionally, the company is focusing on pursuing contracts with major global players. If partnerships are realized, L&K Biomed plans to accelerate the overseas expansion of its entire spinal implant lineup, leveraging its global distribution network, which has been centered around lumbar products.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
L&K Biomed is securing new growth momentum in the global cervical implant market, based on the success of its first clinical application in the U.S. and the commercialization of its premium product.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.